Revisión sistemática de los efectos adversos cutáneos causados por fármacos inhibidores de los puntos de control inmunitario: características, manejo y pronóstico
出版年份 2021 全文链接
标题
Revisión sistemática de los efectos adversos cutáneos causados por fármacos inhibidores de los puntos de control inmunitario: características, manejo y pronóstico
作者
关键词
Immune checkpoint inhibitors, Cutaneous immune-related adverse events, Skin toxicity, Immunotherapy, Programmed cell death protein 1 inhibitors
出版物
Actas Dermo-Sifiliograficas
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-12-31
DOI
10.1016/j.ad.2021.09.005
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital
- (2021) J. Torres-Jiménez et al. Clinical & Translational Oncology
- Incidence of Skin and Respiratory Immune-Related Adverse Events Correlates With Specific Tumor Types in Patients Treated With Checkpoint Inhibitors
- (2021) Lynn M. Rose et al. Frontiers in Oncology
- IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies
- (2021) D.M. Barrios et al. ANNALS OF ONCOLOGY
- Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors
- (2021) Paola Cutroneo et al. Dermatologic Therapy
- Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers
- (2021) Christian D. Sadik et al. Frontiers in Immunology
- Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials
- (2021) Guru P Sonpavde et al. Future Oncology
- Pembrolizumab-induced Stevens–Johnson Syndrome with Severe Ocular Complications
- (2021) Soyoung Ryu et al. OCULAR IMMUNOLOGY AND INFLAMMATION
- Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study
- (2021) M. Guida et al. ESMO Open
- Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system
- (2021) Chen Chen et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review
- (2020) C. de Lorenzi et al. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE
- Radiation recall dermatitis after treatment of stage IV breast cancer with nivolumab: a case report
- (2020) Cole Billena et al. Immunotherapy
- Aggravation of depigmentation for a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: case report
- (2020) Yinghui Xu et al. Immunotherapy
- Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program
- (2020) Javier Jimenez et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Herpes zoster granulomatous dermatitis in metastatic lung cancer treated with nivolumab: A case report
- (2020) Elisa Gozzi et al. Thoracic Cancer
- Sweet’s syndrome under ipilimumab therapy and a brief comparison of the cases in literature
- (2020) Hatime A Yaşar et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo
- (2020) Alexander M. M. Eggermont et al. JAMA Oncology
- Patients with lung cancer undergoing immune checkpoint inhibitors: a meta-analysis of dermatological toxicities
- (2020) Náthali Felícia Mineiro dos Santos Garrett et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis
- (2020) Eleftheria Chorti et al. EUROPEAN JOURNAL OF CANCER
- Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study
- (2020) Taisuke Matsuya et al. JOURNAL OF DERMATOLOGY
- Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study
- (2020) Eiji Nakano et al. JOURNAL OF DERMATOLOGY
- Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab
- (2020) Mariko Ogawa‐Momohara et al. JOURNAL OF DERMATOLOGY
- Generalized Bullous Mucocutaneous Eruption Mimicking Stevens-Johnson Syndrome in the Setting of Immune Checkpoint Inhibition: A Multicenter Case Series
- (2020) Gabriel E. Molina et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Management of immune checkpoint inhibitor-induced bullous pemphigoid
- (2020) Zoe Apalla et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Cutaneous adverse reactions to anti-PD-1 treatment – a systematic review
- (2020) Anne Birgitte Simonsen et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- CME Part I: Immune checkpoint inhibitors to treat cutaneous malignancies
- (2020) Dulce M. Barrios et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
- (2020) Samantha Ellis et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- CME Part II: Immune checkpoint inhibitor-related dermatologic adverse events
- (2020) Amaris N. Geisler et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Risk of scleroderma according to the type of immune checkpoint inhibitors
- (2020) Benjamin Terrier et al. AUTOIMMUNITY REVIEWS
- Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
- (2020) Hiroshi Matsuoka et al. BMC CANCER
- Cutaneous immune-related adverse events to checkpoint inhibitors
- (2020) Neeta Malviya et al. CLINICS IN DERMATOLOGY
- Hypohidrosis as an immune-related adverse event of checkpoint inhibitor therapy
- (2020) Anna E Kersh et al. Immunotherapy
- Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report
- (2020) Megumu Osaki et al. INVESTIGATIONAL NEW DRUGS
- Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management
- (2020) Anastasiya Muntyanu et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- Association of Anti–Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma
- (2020) Angélique Brunot et al. JAMA Dermatology
- Bluish-gray fingernail discoloration due to the use of nivolumab
- (2020) Miguel Michel Ocampo et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature
- (2020) Antonella Cosimati et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- De novo subacute cutaneous lupus erythematosus‐like eruptions in the setting of programmed death‐1 or programmed death ligand‐1 inhibitor therapy: clinicopathological correlation
- (2020) A. N. Bui et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: a retrospective analysis
- (2020) Ai-Tram N. Bui et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Immunotherapy-mediated dermatological adverse events: the urgent need for a common, clinically meaningful, management strategy
- (2020) Zoe Apalla et al. SUPPORTIVE CARE IN CANCER
- Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report
- (2020) Maria Anna Siciliano et al. Frontiers in Oncology
- Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report
- (2020) Sook Jung Yun et al. Translational Lung Cancer Research
- Immune Checkpoint Inhibitor-Associated Scleroderma-Like Syndrome: A Report of a Pembrolizumab-Induced “Eosinophilic Fasciitis-Like” Case and a Review of the Literature
- (2020) Christina Salamaliki et al. Rheumatology and Therapy
- Case Report and Review of 7 Similar Cases in the Literature
- (2020) Angelica P. Trilleras-Gomez et al. JOURNAL OF IMMUNOTHERAPY
- Immune checkpoint-mediated psoriasis: a multicentric European study of 115 patients from European Network for Cutaneous ADverse Event to Oncologic drugs (ENCADO) group.
- (2020) Vasiliki Nikolaou et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer
- (2020) Bairavi Shankar et al. JAMA Oncology
- Treatment Outcomes of Immune-Related Cutaneous Adverse Events
- (2019) Gregory S. Phillips et al. JOURNAL OF CLINICAL ONCOLOGY
- The oncological survival and prognosis of individuals receiving PD-1 inhibitor with and without immunologic cutaneous adverse events
- (2019) L. Chan et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: A review
- (2019) Vignesh Ravi et al. Dermatologic Therapy
- BP180-specific IgG is associated with skin adverse events, therapy response and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
- (2019) Omar Hasan Ali et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System
- (2019) Emanuel Raschi et al. ONCOLOGIST
- Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer
- (2019) Deniz C Guven et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Pruritic bullous skin eruption in a male patient receiving immunotherapy for oropharyngeal cancer
- (2019) Hanjae Lee et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Ipilimumab/nivolumab‐induced pseudolymphoma in a patient with malignant melanoma
- (2019) Noura Ayoubi et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma
- (2019) Ian T. Logan et al. JOURNAL OF IMMUNOTHERAPY
- Vitiligo under anti-PD1 therapy is associated with increased survival in melanoma patients
- (2019) Charlée Nardin et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Angioedema late in the course of adjuvant nivolumab therapy for melanoma
- (2019) Atul Ratra et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Management of immune checkpoint inhibitor‐related dermatologic adverse events
- (2019) Xiaoyan Si et al. Thoracic Cancer
- A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors
- (2018) Adriana T. Lopez et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study
- (2018) Charles Kyung Min Lee et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
- (2018) Jacob Siegel et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity
- (2018) John A. Thompson Journal of the National Comprehensive Cancer Network
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Inhibitor Toxicity in 2018
- (2018) Douglas B. Johnson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institutional, retrospective analysis with stratification of reactions by toxicity and implications for management
- (2018) Emily Coleman et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- PD-1 Blockade–Induced Pruritus Treated with a Mu-Opioid Receptor Antagonist
- (2018) Shawn G. Kwatra et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Vitiligo-like lesions occurring in patients receiving anti-programmed cell death–1 therapies are clinically and biologically distinct from vitiligo
- (2017) Maiana Larsabal et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings
- (2017) V. Sibaud et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Aprepitant for refractory nivolumab-induced pruritus
- (2017) Jiro Ito et al. LUNG CANCER
- Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
- (2016) V.R. Belum et al. EUROPEAN JOURNAL OF CANCER
- Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
- (2016) Jonathan L. Curry et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort
- (2016) Shelley Ji Eun Hwang et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Anti-PD1-induced psoriasis: a study of 21 patients
- (2016) J. Bonigen et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy
- (2016) Veronica J. Shi et al. JAMA Dermatology
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- (2016) Camille Hua et al. JAMA Dermatology
- Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer
- (2016) Constantin A Dasanu et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now